ストックスクリーナーアプリを入手
10.16
0.28%
-0.0285
前日終値:
$10.19
開ける：
$10.16
24時間の取引高:
229
Relative Volume:
0.15
時価総額：
$3.64B
収益：
-
当期純損益:
-
株価収益率:
-5.3757
EPS:
-1.89
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-0.29%
1か月 パフォーマンス:
-80.46%
6か月 パフォーマンス:
-80.46%
1年 パフォーマンス:
-80.46%
1日の値動き範囲:
$10.16
$10.16
1週間の範囲:
$10.14
$10.19
52週間の値動き範囲:
$10.07
$10.45
Churchill Capital Corp Xi Stock (CCXI) Company Profile
Compare CCXI vs LION, XXI, APAD, DMII
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CCXI
Churchill Capital Corp Xi
|
10.16 | 3.64B | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
9.00 | 2.39B | 3.13B | -174.20M | -111.20M | -0.6937 |
|
XXI
Twenty One Capital Inc
|
5.74 | 2.15B | 0 | 0 | 0 | 0.00 |
|
APAD
A Paradise Acquisition Corp
|
10.15 | 1.43B | 0 | 329.20K | -99,600 | 0.012 |
|
DMII
Drugs Made In America Acquisition Ii Corp
|
9.98 | 654.44M | 0 | 0 | 0 | 0.00 |
Churchill Capital Corp Xi Stock (CCXI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-10-11 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-10-11 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-10-08 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-10-08 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2021-07-07 | アップグレード | Stifel | Hold → Buy |
| 2021-05-07 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-05-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-05-07 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2021-05-07 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-05-07 | ダウングレード | Stifel | Buy → Hold |
| 2021-03-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-03-02 | 開始されました | Stifel | Buy |
| 2020-10-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-05-27 | 開始されました | Wells Fargo | Overweight |
| 2020-05-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-26 | 繰り返されました | Piper Jaffray | Overweight |
| 2019-03-27 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2019-02-11 | 開始されました | Piper Jaffray | Overweight |
| 2018-09-07 | 開始されました | B. Riley FBR | Neutral |
| 2018-08-14 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-06-28 | 開始されました | Raymond James | Strong Buy |
| 2018-05-02 | 開始されました | H.C. Wainwright | Buy |
| 2017-02-21 | 開始されました | JMP Securities | Mkt Outperform |
| 2015-05-18 | アップグレード | JP Morgan | Neutral → Overweight |
| 2013-05-20 | 繰り返されました | Stifel | Buy |
| 2012-11-14 | 開始されました | Stifel Nicolaus | Buy |
すべてを表示
Churchill Capital Corp Xi (CCXI) 最新ニュース
Churchill Capital Corp XIUnits (Nasdaq:CCXIU) Stock Quote - FinancialContent
Magnetar Financial LLC Acquires 2,700,000 Shares in Churchill Ca - GuruFocus
DermTech Stock (DMTK)Quote OTC Markets - marketscreener.com
Churchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026 - The Manila Times
Churchill Capital Corp XI Announces Separate Trading of Shares and Warrants - TradingView
US FDA Review Team Split On Amgen’s Tavneos Years Before Withdrawal Request - Citeline News & Insights
Asking Amgen to withdraw Tavneos, FDA revisits years-old data issue - BioCentury
Amgen thumbs-down on FDA’s ask, Tavneos sales continue - BioWorld MedTech
Amgen resists FDA request to pull rare disease drug Tavneos from the market - Fierce Pharma
Amgen’s Revenue Gains Outweigh News That FDA Wants Tavneos Pulled From Market - Citeline News & Insights
Amgen Defends Tavneos Benefit-Risk Profile Following FDA Withdrawal Request - Medical Professionals Reference
US FDA Wants Tavneos Pulled From Market, Amgen Declines - Citeline News & Insights
EMA reviewing Amgen’s vasculitis drug over trial ‘data integrity’ - BioWorld MedTech
Horizon (HRZN) and Monroe Capital (MRCC) outline proxy drive for proposed merger and asset sale - Stock Titan
1 km lidar partnership for safer cars, trains and transport systems - Stock Titan
Rough Price Target for a Promising Quantum Computing Name Working With Nvidia - TheStreet Pro
Churchill Capital Corp X (CCCX) Stock News on Dec. 24, 2025: Infleqtion Quantum SPAC Deal, Latest Catalysts, and What Comes Next - TechStock²
Churchill Capital Corp XI completes $414 million IPO and private placement - Investing.com
Infleqtion Chief Scientist for Quantum Information Dr. Mark Saffman Awarded the John Stewart Bell Prize - Business Wire
U.S. IPO Weekly Recap: Medline Headlined Final Week Before Christmas - Seeking Alpha
Churchill Capital Corp XI completes $414 million IPO on NASDAQ By Investing.com - Investing.com Nigeria
Churchill Capital Corp XI Announces the Pricing of Upsized $360 Million Initial Public Offering - Yahoo Finance
Another SPAC Boom is Coming; And It’s Stronger than Ever - themiddlemarket.com
Deal Watch: Skadden, Davis Polk, Wachtell, Cravath Lead $20B Deals, as Mega M&A Continues - Law.com
IPO NewsUS IPO Weekly Recap: 2 IPOs come to market, pipeline grows ahead of Thanksgiving holiday week - renaissancecapital.com
Canaan (NASDAQ: CAN) closes $72M registered direct offering; ADSs at $1.131 - Stock Titan
Shareholder Alert: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed Against ChemoCentryx, Inc. - Newsfile
Anca Vasculitis Drug Market Set for Dynamic Rise with Key Players ChemoCentryx, Inc. and Vifor Pharma - openPR.com
Trump, Xi to Talk in Person; CPI on Tap; Oh, Boy, Canada! - TheStreet Pro
Steam demo Oct 15 — GCL's Island of Hearts live-action game launches Spring 2026 with creator cast - Stock Titan
Churchill Capital Corp X Shares Jump After Citron Research Calls It a Top Quantum Trade - MSN
First-Ever Bank Rewards to Crypto: JPMorgan to Allow Chase Points Transfer to Coinbase Wallets - Stock Titan
ChemoCentryx Target of Unusually High Options Trading (NASDAQ:CCXI) - 富途牛牛
Immuneering Appoints Dr. Thomas Schall as Chairman of the Board - The Globe and Mail
Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix - TheStreet
Nephrotic Syndrome Pipeline Analysis, 2025 by DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharm - Barchart.com
Latham-Backed Drug Developer's Statements Can't Be Proven False, N.D. Cal. Judge Finds - Law.com
Amgen's ChemoCentryx prevails in investor lawsuit centered on autoimmune drug Tavneos - Fierce Pharma
Pharma Company Beats Investor Suit Over Drug Safety Claims - Law360
Doctored data, protest from trial observers: Lawsuit points to alleged misconduct at Amgen-bought biotech - Fierce Pharma
NVIDIA Certifies AEye's Apollo Lidar for Autonomous Driving Platform, Opening Door to Major Automakers - Stock Titan
Massive Edge AI Deal: Blaize Secures $56M Contract to Power 250K Smart Surveillance Systems in Southeast Asia - Stock Titan
DC-Area REIT Saul Centers Keeps Steady Dividend Stream with Latest $0.59 Payout - Stock Titan
Michael Klein's Latest SPAC Raises Massive $414M IPO as Churchill Capital Sees Strong Demand - Stock Titan
Mullen's Dramatic 1:100 Stock Split Aims to Save Nasdaq StatusKey Details Revealed - Stock Titan
25-Year Pharma Veteran Joins aTyr to Launch First New Sarcoidosis Treatment in 70 Years - Stock Titan
Navigator Medicines Appoints Tausif ‘Tosh’ Butt as Chief Executive Officer and Khurem Farooq as Chairman of the Board of Directors - Business Wire
Bernstein Litowitz Berger & Grossmann LLP Announces Notice of Pendency of Class Action for All Persons and Entities Who Purchased or Otherwise Acquired the Common Stock of ChemoCentryx, Inc. from November 26, 2019 through May 6, 2021, inclusive - Olean Times Herald
Microscopic Polyangiitis (MPA) Treatment Industry to Witness - openPR.com
Amgen opts to sublease Peninsula space taken in $3.9 billion buyout - The Business Journals
ChemoCentryx (NASDAQ:CCXI) Sees Strong Trading Volume on Analyst Upgrade - 富途牛牛
Churchill Capital Corp Xi (CCXI) 財務データ
Churchill Capital Corp Xi (CCXI) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
9.09%
7.42%
大文字化:
|
ボリューム (24 時間):